# Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

> **NCT00402532** · PHASE3 · COMPLETED · sponsor: **Hannover Medical School** · enrollment: 190 (actual)

## Conditions studied

- Lung Transplantation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Mycophenolatmofetil

## Key facts

- **NCT ID:** NCT00402532
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2011-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402532, "Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00402532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*